We came across a bullish thesis on Sarepta Therapeutics, Inc. (SRPT) on Disruptive analytics’ Substack by Magnus Ofstad. In ...

Sarepta Therapeutics' Elevidys for DMD shows revenue potential, with market cap justified at $11.4bn and potential for >50% ...

In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), with a price ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $151.64, a high estimate of ...

Mizuho Securities analyst Uy Ear maintained a Hold rating on Revance Therapeutics (RVNC – Research Report) yesterday and set a price target of ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported ...

Assenagon Asset Management S.A. trimmed its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 62.2% in the ...

Mike Morin: We’re very proud to represent Sarepta Therapeutics, an innovative biotechnology company that focuses exclusively ...

Analysts at HC Wainwright raised their FY2024 earnings estimates for Sarepta Therapeutics in a note issued to investors on ...

Sarepta Therapeutics’ Duchenne muscular dystrophy therapy Elevidys handily beat analysts’ expectations in the fourth quarter ...

Sarepta Therapeutics exceeded 2024 net product revenue guidance and reaffirmed its 2025 outlook, partly due to strong growth for Duchenne muscular dystrophy drug Elevidys.